• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study
CONCLUSIONS: Confirmation of presence or absence of metastases is necessary before starting ICIs. After temozolomide failure, ICIs appear as a good therapeutic option for PCs, especially for corticotroph carcinomas. Negative PD-L1 staining and very low CD8+ T cell infiltration in the tumor center should not preclude ICI administration in corticotroph carcinomas.PMID:36111659 | DOI:10.1530/EJE-22-0647
Source: European Journal of Endocrinology - September 16, 2022 Category: Endocrinology Authors: Mirela Diana Ilie Chiara Villa Thomas Cuny Christine Cortet Guillaume Assi é Bertrand Baussart Mathilde Cancel Philippe Chanson B énédicte Decoudier Elise Deluche Anna Luisa Di Stefano Delphine Drui Stephan Gaillard Bernard Goichot Olivier Huillard Ant Source Type: research

Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas
CONCLUSIONS: With high-quality WGS data and comprehensive methods, we identified the landscape of driver gene events and druggable targets in glioblastoma patients.PMID:35047820 | PMC:PMC8760899 | DOI:10.1093/noajnl/vdab177
Source: Adv Data - January 20, 2022 Category: Epidemiology Authors: Wesley S van de Geer Youri Hoogstrate Kaspar Draaisma Pierre A Robe Sander Bins Ron H J Mathijssen Pim French Harmen J G van de Werken Filip Y F de Vos Source Type: research

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
Conclusion Hem-irAEs are potentially life-threatening complications of ICIs that require a high level of clinical suspicion. Ir-TCP is amongst the most frequently reported hem-irAEs. Due to its low incidence and the lack of specific diagnostic criteria, ir-TCP may be underdiagnosed and possibly underreported. The diagnosis is based on exclusion of other causes of TCP together with clinical features that suggest an immune event such as the refractoriness to platelet transfusions and response to corticosteroids. During clinical development, a systematic analysis of ir-TCP cases at clinical study and program level is of outm...
Source: Frontiers in Pharmacology - April 25, 2019 Category: Drugs & Pharmacology Source Type: research